News & Events
-
August 1, 2015
Towards Host-Directed Therapies for Tuberculosis
Zumla A, Maeurer M, Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JBW, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SHE, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS. Towards Host-Directed Therapies for Tuberculosis. Nature Reviews Drug Discovery. 2015 Aug;14(8):511–2.
-
July 28, 2015
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm
Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2015 Jul 28;61 Suppl 1:S18–24.
-
July 14, 2015
The Predictive Safety Testing Consortium: Safety Biomarkers, Collaboration, and Qualification
Sauer JM, Walker EG, Porter AC. The Predictive Safety Testing Consortium: Safety Biomarkers, Collaboration, and Qualification. Journal of Medicines Development Sciences. 2015 Jul 14;1(1).
- June 26, 2015
-
June 15, 2015
Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis
Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis. The Journal of Infectious Diseases. 2015 Jun 15;211 Suppl 3:S83–95.
